Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • As a Strong Start Turns Sour, What’s Next for the Leveraged Finance Market?

    Following a solid run of issuance in 2025, expectations for the leveraged finance market were high heading into 2026.

    Read more

  • Planning Your Assets in Case of a Divorce

    These steps can help reduce financial risk and preserve your family’s wealth.

    Read more

  • Why the Youth Enrichment Services Market Is Growing (and Recession Resilient)

    As parents increasingly look to provide their kids with an edge, the youth enrichment sector is booming—and emerging as a highly compelling investment category.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures